NOVAVAX INC (NVAX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NVAX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NVAX | ["Industry Experience","Executive Leadership","Cybersecurity/IT/AI","Public Company Board"] | [] | 2026 |
Biography sourced from the proxy statement filing.
AGE 68 INDEPENDENT DIRECTOR SINCE 2025 COMMITTEES Compensation Research & Development JOHN W. SHIVER, PH.D. CAREER HIGHLIGHTS Vibrant Biomedicines Head of Research and Development (2024 to present) F-Prime Capital Special Advisor (2021 to present) University of Pennsylvania Adjunct Professor, College of Medicine (2008 to present) IGM ID Chief Strategy Officer, Infectious Disease Business Unit (2021 to 2023) Sanofi Pasteur Senior Vice President (2013 to 2020) Merck & Co., Inc. Vice President, Vaccine Basic Research & Franchise Head (2007 to 2013) Vice President, Vaccines & Biologics Research (2004 to 2007) Executive Director, Vaccines Research (1991 to 2004) OTHER CURRENT DIRECTORSHIPS Calder Biosciences AuraVax Therapeutics EDUCATION Ph.D. in Physical Chemistry, University of Florida Bachelor of Science in Chemistry and Mathematics, Wofford College KEY SKILLS AND QUALIFICATIONS Dr. Shiver is well-suited to serve on our Board due to his more than 30 years of experience in pharmaceutical research and development and leadership of teams of scientists working with infectious and non-infectious diseases. Dr. Shiver also has experience with machine learning and artificial intelligence for the development of vaccines candidates. Dr. Shiver brings experience serving on various scientific advisory boards and committees.